Evidence map›Paper›PMID 26491161›Full record

ArticleJournal of virology2016

A Naturally Occurring Domestic Cat APOBEC3 Variant Confers Resistance to Feline Immunodeficiency Virus Infection.

Rokusuke Yoshikawa, Taisuke Izumi, Eri Yamada, Yusuke Nakano, Naoko Misawa, Fengrong Ren, Michael A Carpenter, Terumasa Ikeda, Carsten Münk, Reuben S Harris and 3 more

Abstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Absence ofViruses · 2018
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rokusuke YoshikawaLaboratory of Viral Pathogenesis, Institute for Virus Research, Kyoto University, Kyoto, Japan.
Taisuke IzumiLaboratory of Viral Pathogenesis, Institute for Virus Research, Kyoto University, Kyoto, Japan Department of Microbiology, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan CREST, Japan Science and Technology Agency, Saitama, Japan.
Eri YamadaLaboratory of Viral Pathogenesis, Institute for Virus Research, Kyoto University, Kyoto, Japan.
Yusuke NakanoLaboratory of Viral Pathogenesis, Institute for Virus Research, Kyoto University, Kyoto, Japan.
Naoko MisawaLaboratory of Viral Pathogenesis, Institute for Virus Research, Kyoto University, Kyoto, Japan.
Fengrong RenDepartment of Bioinformatics, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.
Michael A CarpenterDepartment of Biochemistry, Molecular Biology and Biophysics, Institute for Molecular Virology, Masonic Cancer Center, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, USA.
Terumasa IkedaDepartment of Biochemistry, Molecular Biology and Biophysics, Institute for Molecular Virology, Masonic Cancer Center, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, USA.
Carsten MünkClinic for Gastroenterology, Hepatology, and Infectiology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Reuben S HarrisDepartment of Biochemistry, Molecular Biology and Biophysics, Institute for Molecular Virology, Masonic Cancer Center, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, USA Howard Hughes Medical Institute, University of Minnesota, Minneapolis, Minnesota, USA.
Takayuki MiyazawaLaboratory of Signal Transduction, Institute for Virus Research, Kyoto University, Kyoto, Japan Laboratory of Virolution, Institute for Virus Research, Kyoto University, Kyoto, Japan.
Yoshio KoyanagiLaboratory of Viral Pathogenesis, Institute for Virus Research, Kyoto University, Kyoto, Japan.
Kei SatoLaboratory of Viral Pathogenesis, Institute for Virus Research, Kyoto University, Kyoto, Japan CREST, Japan Science and Technology Agency, Saitama, Japan ksato@virus.kyoto-u.ac.jp.

Funding

Structural Characterization of APOBECS's Atomic interactionsP01GM091743 · NIGMS · UNIVERSITY OF MINNESOTA · PI KOTLER, MOSHE · 2011 to 2015
$10.1M
APOBEC3 Proteins in HIV RestrictionR37AI064046 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HARRIS, REUBEN S · 2015 to 2024
$4.2M
APOBEC proteins and uracil in retrovirus restrictionR01AI064046 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI HARRIS, REUBEN S · 2005 to 2014
$3.0M
NIAID NIH HHS R01 AI064046NIAID NIH HHS R37 AI064046NIGMS NIH HHS P01 GM091743
6 · The paper itself

Abstract

unlabelledApolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3; A3) DNA cytosine deaminases can be incorporated into progeny virions and inhibit lentiviral replication. On the other hand, viral infectivity factor (Vif) of lentiviruses antagonizes A3-mediated antiviral activities by degrading A3 proteins. It is known that domestic cat (Felis catus) APOBEC3Z3 (A3Z3), the ortholog of human APOBEC3H, potently suppresses the infectivity of vif-defective feline immunodeficiency virus (FIV). Although a recent report has shown that domestic cat encodes 7 haplotypes (hap I to hap VII) of A3Z3, the relevance of A3Z3 polymorphism in domestic cats with FIV Vif has not yet been addressed. In this study, we demonstrated that these feline A3Z3 variants suppress vif-defective FIV infectivity. We also revealed that codon 65 of feline A3Z3 is a positively selected site and that A3Z3 hap V is subject to positive selection during evolution. It is particularly noteworthy that feline A3Z3 hap V is resistant to FIV Vif-mediated degradation and still inhibits vif-proficient viral infection. Moreover, the side chain size, but not the hydrophobicity, of the amino acid at position 65 determines the resistance to FIV Vif-mediated degradation. Furthermore, phylogenetic analyses have led to the inference that feline A3Z3 hap V emerged approximately 60,000 years ago. Taken together, these findings suggest that feline A3Z3 hap V may have been selected for escape from an ancestral FIV. This is the first evidence for an evolutionary "arms race" between the domestic cat and its cognate lentivirus. IMPORTANCE: Gene diversity and selective pressure are intriguing topics in the field of evolutionary biology. A direct interaction between a cellular protein and a viral protein can precipitate an evolutionary arms race between host and virus. One example is primate APOBEC3G, which potently restricts the replication of primate lentiviruses (e.g., human immunodeficiency virus type 1 [HIV-1] and simian immunodeficiency virus [SIV]) if its activity is not counteracted by the viral Vif protein. Here we investigate the ability of 7 naturally occurring variants of feline APOBEC3, APOBEC3Z3 (A3Z3), to inhibit FIV replication. Interestingly, one feline A3Z3 variant is dominant, restrictive, and naturally resistant to FIV Vif-mediated degradation. Phylogenetic analyses revealed that the ancestral change that generated this variant could have been caused by positive Darwinian selection, presumably due to an ancestral FIV infection. The experimental-phylogenetic investigation sheds light on the evolutionary history of the domestic cat, which was likely influenced by lentiviral infection.

Indexed as

Host-Pathogen InteractionsImmunity, InnateVirus ReplicationAnimalsCatsCytidine DeaminaseEvolution, MolecularGene Products, vifImmunodeficiency Virus, FelineSelection, GeneticCytidine DeaminaseGene Products, vif

Identifiers

PMID26491161
PMCPMC4702554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.